Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia’s ...
BAR HARBOR -- A big part of the visitor experience at Acadia National Park is reopening. The majority of the park loop road ...
With the FDA’s first approval for a treatment for Rett syndrome now under its belt, Daybue maker Acadia Pharmaceuticals has debuted its latest effort to raise awareness around the rare disease.
Canyon Capital sold 521,774 shares of Acadia Healthcare in the fourth quarter. The quarter-end position value fell by approximately $12.92 million as a result. Post-trade, the fund held zero shares of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results